Nateglinide improves glycaemic control when added to metformin monotherapy: Results of a randomized trial with type 2 diabetes patients

Diabetes, Obesity and Metabolism

Volumn 4, Issue 3, 2002, Pages 177-186

  Marre, M ^a   Van Gaal, L ^b   Usadel, K H ^c   Ball, M ^d   Whatmough, I ^d   Guitard, C ^d  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c GOETHE UNIVERSITY   (Germany)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Glycaemic control; Hypoglycaemia; Metformin; Nateglinide; Type 2 diabetes

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIDIABETIC AGENT; CORTICOSTEROID; DEXTRO PHENYLALANINE; DICOUMAROL DERIVATIVE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; LIPID; METFORMIN; NATEGLINIDE; PLACEBO; TRIACYLGLYCEROL; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

EID: 0036265936     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2002.00196.x     Document Type: Article

References (26)

1. Glycaemic control with diet, sulphonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49)
2. Metformin
3. Pharmacologic therapy for type 2 diabetes mellitus
4. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
5. Overview of current therapeutic options in type 2 diabetes: Rationale for combining oral agents with insulin therapy
6. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. Diabetes Epidemiology: Collaborative analysis of diagnostic criteria in Europe
7. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance
8. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus
9. Pathophysiology of insulin secretion in non-insulin-dependent diabetes mellitus
10. N-acylphenylalanines and related compounds. A new class of oral hypoglycaemic agents
11. Mealtime glucose regulation with nateglinide in healthy volunteers: Comparison with repaglinide and placebo
12. Reduced risk of delayed hypoglycemia with nateglinide compared to repaglinide
13. Efficacy of metformin in type 2 diabetes: Results of a double-blind, placebo-controlled, dose-response trial
14. Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial
15. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia
16. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes
17. Effects of the new oral hypoglycemic agent nateglinide on insulin secretion in type 2 diabetes mellitus
18. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomised prospective 6-year study
19. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: A double-blind controlled study
20. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes
21. Sulfonylureas in non-insulin-dependent diabetes mellitus
22. UK Prospective Diabetes Study 33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes
23. Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects
24. Rates of hypoglycaemia in users of sulfonylureas
25. Comparative tolerability of sulphonylureas in diabetes mellitus
26. Relative efficacy of randomly allocated diet, sulphonylurea, insulin or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. UK Prospective Diabetes Study 13